Day-care Unit for Patients With Refractory Heart Failure (DayCare-HF)

May 25, 2020 updated by: Mariusz Gasior, Silesian Centre for Heart Diseases

Day-care Unit for Patients With Refractory Heart Failure - a Single-centre Study

The Day-Care Unit for Patients With Refractory Heart Failure (DayCare-HF) is an observational study on selected patients with advanced refractory heart failure. The purpose of the study was to examine the comprehensive management of HF in the day-care unit in terms of the safety and its impact on the rehospitalization and mortality rates in patients with advanced refractory HF.

Study Overview

Detailed Description

The Day-Care Unit for Patients With Refractory Heart Failure (DayCare-HF) is a single-center observational study conducted in the 3rd Department of Cardiology, School of Medicine with the Division of Dentistry in Zabrze, Medical University of Silesia in Katowice, Silesian Centre for Heart Disease in Zabrze, Poland.

The main objective of the DayCare-HF is to verify the hypothesis that comprehensive and multidisciplinary day-care management of patients with refractory heart failure (HF) is safe and beneficial in terms of hospital readmission due to HF and al cause mortality.

The study population is formed by selected patients with heart failure, hospitalized in cardiology wards and intensive cardiac care unit of Silesian Centre for Heart Disease, who fulfilled eligibility criteria.

During the scheduled visits comprehensive medical service is provided, including education, diagnostic tools (electrocardiography, transthoracic echocardiography, implanted cardioverter defibrillator (ICD) / cardiac resynchronization therapy device (CRT) interrogation and additional treatment (intravenous loop diuretic, dobutamine, vasodilators administration).

The patients are under constant follow-up for major adverse events, heart transplantation, hospital readmissions due to HF and all cause mortality.

Study Type

Interventional

Enrollment (Anticipated)

200

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Silesia
      • Zabrze, Silesia, Poland, 41-800
        • Silesian Centre for Heart Disease

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Optimally decongested heart failure in New York Heart Association (NYHA) class II-IV, treated for at least 6 months
  2. Performance of all possible reparative procedures if indications were present (cardiac revascularization, correction of valvular heart disease, cardiac ablation, cardiac resynchronization therapy)
  3. Implantation of cardioverter-defibrillator (ICD) if applicable
  4. At least two unplanned hospitalizations for heart failure during preceding 6 months

Exclusion Criteria:

  1. Inability to travel to the unit
  2. Non-compliance with the medical recommendations

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: TREATMENT
  • Allocation: NA
  • Interventional Model: SINGLE_GROUP
  • Masking: NONE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
OTHER: DayCare-HF
Comprehensive service in day-care unit, including education, diagnostic tools (i.e. electrocardiography, transthoracic echocardiography, implanted cardioverter defibrillator (ICD) / cardiac resynchronization therapy device (CRT) interrogation and possibility of intravenous drug administration (i.e. loop diuretics, dobutamine).

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Number of participants with rehospitalization due to heart failure decompensation
Time Frame: From date of inclusion until the date of death from any cause, assessed up to 1 year
From date of inclusion until the date of death from any cause, assessed up to 1 year

Secondary Outcome Measures

Outcome Measure
Time Frame
Number of participants with major adverse cardiovascular event
Time Frame: From date of inclusion until the date of death from any cause, assessed up to 1 year
From date of inclusion until the date of death from any cause, assessed up to 1 year
Number of participants with reported deaths from any cause
Time Frame: From date of inclusion until the date of death from any cause, assessed up to 1 year
From date of inclusion until the date of death from any cause, assessed up to 1 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

April 1, 2016

Primary Completion (ANTICIPATED)

December 1, 2020

Study Completion (ANTICIPATED)

December 1, 2022

Study Registration Dates

First Submitted

February 12, 2017

First Submitted That Met QC Criteria

February 14, 2017

First Posted (ACTUAL)

February 17, 2017

Study Record Updates

Last Update Posted (ACTUAL)

May 27, 2020

Last Update Submitted That Met QC Criteria

May 25, 2020

Last Verified

May 1, 2020

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • DayCare-HF
  • DCHFU (OTHER: Silesian Centre for Heart Disease)

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe